<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03193086</url>
  </required_header>
  <id_info>
    <org_study_id>GZ-2016-11629</org_study_id>
    <nct_id>NCT03193086</nct_id>
  </id_info>
  <brief_title>The Effect of Alemtuzumab on the Blood-brain-barrier and the Brain's Metabolism in Multiple Sclerosis Patients</brief_title>
  <official_title>The Effect of Alemtuzumab on the Blood-brain-barrier and Cerebral Metabolism in Multiple Sclerosis Patients; a New MRI Method for Treatment Response Evaluation in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glostrup University Hospital, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Glostrup University Hospital, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The development and progression of multiple sclerosis seem to be driven by concomitant
      inflammation and, to a less well-defined degree, disturbances in metabolism of individual
      cells of the human central nervous system as well as changes in the dynamical supply of blood
      to the brain. These alterations in normal physiology can be quantified by investigating the
      change in specific parameters over the time course of multiple sclerosis evolution. Amongst
      these specific parameters, the ability of the so-called blood-brain-barrier to selectively
      filter nutrients from the blood stream prior to passage into the nervous tissue, is disrupted
      in multiple sclerosis, and the severity of this deficiency seem to be related to the
      underlying disease burden. The present study utilises a novel imaging technology in order to
      monitor changes in the integrity of the blood-brain-barrier over the course of treatment with
      a biological disease modifying agent known as alemtuzumab. Alemtuzumab is a potent
      immunosuppressant drug. It is hypothesised that alemtuzumab reverts the deficiency in
      blood-brain-barrier integrity and, conversely, the severity of blood-brain-barrier disruption
      at several time points during alemtuzumab treatment can be utilised as prognostic marker for
      the requirement of additional administration of alemtuzumab beyond the regular treatment
      regimen. In addition, several other factors are investigated by advanced imaging techniques
      in combination with blood and urine samples in order to elucidate the possible underlying
      mechanism of alemtuzumab efficacy. It is hypothesized that alemtuzumab normalises metabolic
      alterations and changes in the blood supply through resolution of inflammation in the brains
      of multiple sclerosis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Traditional paraclinical measures of disease severity in multiple sclerosis (MS), such as T2
      lesion load as measured by magnetic resonance imaging (MRI), are poorly correlated with
      long-term disability accumulation. Other surrogate markers of the current and future disease
      burden are therefore needed. The permeability of the blood-brain-barrier (BBB) seems to
      better reflect the substantial, subclinical disease activity underlying MS progression. Its
      useful role as a prognostic marker in MS has been clearly established by the recent
      observation that BBB permeability increase in optic neuritis patients is associated with
      conversion to definite MS. BBB permeability can be quantified, in a convenient manner to the
      patient, using Dynamic-Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) by modelling
      the change in intrinsic MRI parameters of the human brain in response to the administration
      of a bolus contrast agent. Alemtuzumab is a disease modifying drug that depletes T- and
      B-cells. It is administered in two series separated by 12 months, as explained in the section
      &quot;Groups and Interventions.&quot; The number of relapses are significantly reduced as compared to
      other efficacious treatments in MS, as demonstrated recently (study referred to by its
      ClinicalTrials.gov identifier NCT00050778). The efficacy of alemtuzumab in resolving the
      inflammatory burden underlying relapses is, thus, well-established. Its influence on
      subclinical inflammation, however, remains unknown. It is the aim of the present study to
      investigate whether or not the latter influence is of importance, and, consequently, can be
      used to evaluate the need for an intensified treatment, in the form of an additional series
      of alemtuzumab administration.

      BBB permeability changes, as surrogate markers of subclinical inflammation, are measured
      every 6 months just prior to and during the course of alemtuzumab treatment. In order to
      elucidate other potential mechanisms involved in disability accumulation, biomarkers and
      MRI-derived parameters are evaluated concomitantly. Specifically, the role of metabolic
      changes are investigated using MRI methods that measures blood perfusion and oxygen
      consumption. Secondarily, the BBB permeability and metabolic changes are correlated to novel
      biomarkers of inflammation and neurodegeneration in serum and urine, as well as conventional
      measures of MS severity: annual relapse rate, Expanded Disability Severity Score, MRI-derived
      estimates of disease activity and brain atrophy.

      35 patients are included in the study in order to achieve enough statistical power and
      accommodate drop-outs. Patients are MRI scanned at baseline, 6 months after alemtuzumab
      treatment, and, finally, prior to administration of the second series of alemtuzumab 12
      months after the baseline MRI scanning. At each time point, the patient's disease status is
      evaluated by an experienced neurologist, and urine and serum samples are obtained. Repeated
      Measures Analysis Of Variance (ANOVA) will be used to evaluate changes of permeability of the
      BBB and metabolic parameters at different time points, and baseline characteristics, such as
      prednisolone treatment will be implemented as between-subjects covariates. Logistic
      regression will be applied to estimate the ability of BBB permeability changes to predict the
      need for additional series of alemtuzumab administration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Blood-Brain-Barrier Permeability</measure>
    <time_frame>1 year</time_frame>
    <description>Blood-Brain-Barrier Permeability as measured by Dynamic-Contrast-Enhanced MRI (DCE-MRI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxygen Consumption</measure>
    <time_frame>1 year</time_frame>
    <description>The Cerebral Metabolic Rate of Oxygen Consumption as measured by a novel MRI technique</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral perfusion</measure>
    <time_frame>1 year</time_frame>
    <description>Quantification of cerebral perfusion using DCE-MRI and Arterial-Spin-Labelling MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diffusion Tensor MRI parameters and MR spectroscopy metabolite concentrations</measure>
    <time_frame>1 year</time_frame>
    <description>Measurement of changes in microstructural organization as measured by Diffusion Tensor MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain atrophy</measure>
    <time_frame>2 years</time_frame>
    <description>Voxel-Based-Morphometry of grey and white matter utilizing high-resolution MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Severity of Disease</measure>
    <time_frame>1 year</time_frame>
    <description>Estimation of disease severity by the Expanded Disability Severity Scale (EDSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse frequency</measure>
    <time_frame>1 year</time_frame>
    <description>Number of relapses during follow-up and past history</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma markers of Blood-Brain-Barrier breakdown</measure>
    <time_frame>1 year</time_frame>
    <description>Detection of markers associated with Blood-Brain-Barrier breakdown nervous system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma markers of neuronal damage</measure>
    <time_frame>1 year</time_frame>
    <description>Detection of markers associated with neuronal damage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary markers of inflammation</measure>
    <time_frame>1 year</time_frame>
    <description>Detection of markers associated with inflammatory activity specific to macrophages/microglia in the human central nervous system</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Alemtuzumab treated MS patients</arm_group_label>
    <description>Those with Multiple Sclerosis that have commenced therapy with alemtuzumab (60 mg infusion over the course of 5 days) and completed treatment with alemtuzumab (additional 36 mg infusion during the course of 3 days, 12 months later).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alemtuzumab</intervention_name>
    <description>Alemtuzumab is administered to eligible patients in accordance with established treatment regimes. Initially 60 mg of alemtuzumab is injected intravenously over the course of 5 days. The first treatment series is followed by the injection of 36 mg of alemtuzumab over the course of 3 days 12 months later. During both drug interventions, the transient exacerbation in disease severity is alleviated by concomitant steroid therapy.</description>
    <arm_group_label>Alemtuzumab treated MS patients</arm_group_label>
    <other_name>Lemtrada</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma, urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients are recruited from the two dedicated MS clinics in the secondary health care
        sector of the danish capital region.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis of Relapsing-Remitting Multiple Sclerosis

          -  Eligible for alemtuzumab treatment at Glostrup Hospital or The Danish Kingdom Hospital

          -  Subjects must be deemed physically and mentally able to participate in the study

        Exclusion Criteria:

          -  Contraindications to MRI scanning (pregnancy, pacemakers, claustrophobia, extreme
             obesity)

          -  Contraindications to the use of MRI contrast agents (kidney disease, previous allergic
             reactions)

          -  Conflicting disorders (e.g. disorders with a systemic, inflammatory component)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik BW Larsson, MD, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Functional Imaging Unit, Department of Clinical Physiology, Nuclear medicine and PET, Glostrup Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter F Svane, MD</last_name>
    <phone>93906653</phone>
    <phone_ext>45</phone_ext>
    <email>peter.frederiksen.svane@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stig P Cramer, MD, PhD</last_name>
    <phone>38634624</phone>
    <phone_ext>45</phone_ext>
    <email>stig.praestekjaer.cramer@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Functional Imaging Unit, Department of Clinical Physiology, Nuclear medicine and PET, Glostrup Hospital</name>
      <address>
        <city>Glostrup</city>
        <state>Copenhagen Capital Region</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter F Svane, MD</last_name>
      <phone>93906653</phone>
      <phone_ext>45</phone_ext>
      <email>peter.frederiksen.svane@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Stig P Cramer, MD, PhD</last_name>
      <phone>38634624</phone>
      <phone_ext>45</phone_ext>
      <email>stig.praestekjaer.cramer@regionh.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol. 2002 Jun;15(3):239-45. Review.</citation>
    <PMID>12045719</PMID>
  </reference>
  <reference>
    <citation>Cramer SP, Larsson HB. Accurate determination of blood-brain barrier permeability using dynamic contrast-enhanced T1-weighted MRI: a simulation and in vivo study on healthy subjects and multiple sclerosis patients. J Cereb Blood Flow Metab. 2014 Oct;34(10):1655-65. doi: 10.1038/jcbfm.2014.126. Epub 2014 Jul 30.</citation>
    <PMID>25074746</PMID>
  </reference>
  <reference>
    <citation>Broholm H, Andersen B, Wanscher B, Frederiksen JL, Rubin I, Pakkenberg B, Larsson HB, Lauritzen M. Nitric oxide synthase expression and enzymatic activity in multiple sclerosis. Acta Neurol Scand. 2004 Apr;109(4):261-9.</citation>
    <PMID>15016008</PMID>
  </reference>
  <reference>
    <citation>Cramer SP, Modvig S, Simonsen HJ, Frederiksen JL, Larsson HB. Permeability of the blood-brain barrier predicts conversion from optic neuritis to multiple sclerosis. Brain. 2015 Sep;138(Pt 9):2571-83. doi: 10.1093/brain/awv203. Epub 2015 Jul 17.</citation>
    <PMID>26187333</PMID>
  </reference>
  <reference>
    <citation>D'haeseleer M, Cambron M, Vanopdenbosch L, De Keyser J. Vascular aspects of multiple sclerosis. Lancet Neurol. 2011 Jul;10(7):657-66. doi: 10.1016/S1474-4422(11)70105-3. Review.</citation>
    <PMID>21683931</PMID>
  </reference>
  <reference>
    <citation>Gauthier SA, Berger AM, Liptak Z, Duan Y, Egorova S, Buckle GJ, Glanz BI, Khoury SJ, Bakshi R, Weiner HL, Guttmann CR. Rate of brain atrophy in benign vs early multiple sclerosis. Arch Neurol. 2009 Feb;66(2):234-7. doi: 10.1001/archneurol.2008.567.</citation>
    <PMID>19204160</PMID>
  </reference>
  <reference>
    <citation>Ge Y, Zhang Z, Lu H, Tang L, Jaggi H, Herbert J, Babb JS, Rusinek H, Grossman RI. Characterizing brain oxygen metabolism in patients with multiple sclerosis with T2-relaxation-under-spin-tagging MRI. J Cereb Blood Flow Metab. 2012 Mar;32(3):403-12. doi: 10.1038/jcbfm.2011.191. Epub 2012 Jan 18.</citation>
    <PMID>22252237</PMID>
  </reference>
  <reference>
    <citation>De Keyser J, Steen C, Mostert JP, Koch MW. Hypoperfusion of the cerebral white matter in multiple sclerosis: possible mechanisms and pathophysiological significance. J Cereb Blood Flow Metab. 2008 Oct;28(10):1645-51. doi: 10.1038/jcbfm.2008.72. Epub 2008 Jul 2. Review.</citation>
    <PMID>18594554</PMID>
  </reference>
  <reference>
    <citation>Larsson HB, Stubgaard M, Frederiksen JL, Jensen M, Henriksen O, Paulson OB. Quantitation of blood-brain barrier defect by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors. Magn Reson Med. 1990 Oct;16(1):117-31.</citation>
    <PMID>2255233</PMID>
  </reference>
  <reference>
    <citation>Larsson HB, Courivaud F, Rostrup E, Hansen AE. Measurement of brain perfusion, blood volume, and blood-brain barrier permeability, using dynamic contrast-enhanced T(1)-weighted MRI at 3 tesla. Magn Reson Med. 2009 Nov;62(5):1270-81. doi: 10.1002/mrm.22136.</citation>
    <PMID>19780145</PMID>
  </reference>
  <reference>
    <citation>Law M, Saindane AM, Ge Y, Babb JS, Johnson G, Mannon LJ, Herbert J, Grossman RI. Microvascular abnormality in relapsing-remitting multiple sclerosis: perfusion MR imaging findings in normal-appearing white matter. Radiology. 2004 Jun;231(3):645-52.</citation>
    <PMID>15163806</PMID>
  </reference>
  <reference>
    <citation>Naismith RT, Cross AH. Enhancing our understanding of white matter changes in early multiple sclerosis. Brain. 2015 Sep;138(Pt 9):2465-6. doi: 10.1093/brain/awv196.</citation>
    <PMID>26304148</PMID>
  </reference>
  <reference>
    <citation>Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, Ebers GC. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain. 2010 Jul;133(Pt 7):1914-29. doi: 10.1093/brain/awq118. Epub 2010 Jun 9.</citation>
    <PMID>20534650</PMID>
  </reference>
  <reference>
    <citation>Steen C, D'haeseleer M, Hoogduin JM, Fierens Y, Cambron M, Mostert JP, Heersema DJ, Koch MW, De Keyser J. Cerebral white matter blood flow and energy metabolism in multiple sclerosis. Mult Scler. 2013 Sep;19(10):1282-9. doi: 10.1177/1352458513477228. Epub 2013 Feb 21.</citation>
    <PMID>23428956</PMID>
  </reference>
  <reference>
    <citation>Sun X, Tanaka M, Kondo S, Okamoto K, Hirai S. Clinical significance of reduced cerebral metabolism in multiple sclerosis: a combined PET and MRI study. Ann Nucl Med. 1998 Apr;12(2):89-94.</citation>
    <PMID>9637279</PMID>
  </reference>
  <reference>
    <citation>Tuohy O, Costelloe L, Hill-Cawthorne G, Bjornson I, Harding K, Robertson N, May K, Button T, Azzopardi L, Kousin-Ezewu O, Fahey MT, Jones J, Compston DA, Coles A. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry. 2015 Feb;86(2):208-15. doi: 10.1136/jnnp-2014-307721. Epub 2014 May 21.</citation>
    <PMID>24849515</PMID>
  </reference>
  <reference>
    <citation>Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Skoromets A, Stolyarov I, Bass A, Sullivan H, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA. Alemtuzumab more effective than interferon Î²-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology. 2012 Apr 3;78(14):1069-78. doi: 10.1212/WNL.0b013e31824e8ee7. Epub 2012 Mar 21.</citation>
    <PMID>22442431</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2017</study_first_submitted>
  <study_first_submitted_qc>June 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2017</study_first_posted>
  <last_update_submitted>June 16, 2017</last_update_submitted>
  <last_update_submitted_qc>June 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Glostrup University Hospital, Copenhagen</investigator_affiliation>
    <investigator_full_name>Peter FredSvan</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Blood-Brain-Barrier</keyword>
  <keyword>Treatment response</keyword>
  <keyword>Metabolism</keyword>
  <keyword>Alemtuzumab</keyword>
  <keyword>Perfusion</keyword>
  <keyword>Oxygen consumption</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

